Physician profile
Mark Shahram Shahin
NPI 1568440451
$914,133.19
in general payments reported to CMS, 2019-2025
52 companies · $177K in 2025
The $177K reported for 2025 was more than what 99% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147K · 2020: $83K · 2021: $83K · 2022: $146K · 2023: $107K · 2024: $171K · 2025: $177K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $316K · Travel and Lodging: $70K · Consulting Fee: $49K · Food and Beverage: $16K · Education: $4,507 · Honoraria: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $315,691.50 |
| Travel and Lodging | $69,517.90 |
| Consulting Fee | $48,697.50 |
| Food and Beverage | $15,980.66 |
| Education | $4,507.18 |
| Honoraria | $425.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $448,413.21 | 2020-2025 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals Lp | $118,563.64 | 2019-2025 | Lynparza, Enhertu, Calquence |
| Merck Sharp & Dohme LLC | $96,800.28 | 2019-2025 | Keytruda, Lynparza |
| Tesaro, INC. | $72,386.32 | 2019 | |
| Abbvie INC. | $43,716.88 | 2024-2025 | |
| Genmab U.S., INC. | $43,136.94 | 2022-2025 | Tivdak, Epkinly |
| Seagen INC. | $21,393.86 | 2021-2023 | |
| Immunogen, INC. | $19,632.72 | 2023 | Elahere |
| Biom'Up Sa | $12,651.18 | 2019 | |
| Eisai INC. | $12,235.10 | 2019-2025 | |
| Corcept Therapeutics | $10,973.15 | 2024-2025 | Korlym |
| Intuitive Surgical, INC. | $5,537.00 | 2022-2025 | Da Vinci Surgical System |
| Pfizer INC. | $1,740.00 | 2024-2025 | |
| Stryker Corporation | $1,605.37 | 2019-2023 | 1688 |
| Karyopharm Therapeutics INC. | $823.08 | 2024-2025 | Xpovio |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $769.37 | 2023-2024 | Myrisk, Precisetumor |
| Baxter Healthcare | $698.76 | 2019-2023 | Floseal |
| Aspira Women'S Health INC | $600.00 | 2020 | |
| Clovis Oncology, INC. | $363.53 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $240.17 | 2024-2025 | |
| Dilon Technologies, INC. | $172.36 | 2024 | Hemoblast Bellows |
| Caris Mpi, INC. | $165.65 | 2025 | Mi Cancer Seek |
| Coopersurgical, INC. | $154.94 | 2019-2023 | Wallach Cryosurgical Equipment |
| Foundation Medicine, INC. | $122.94 | 2019 | |
| Novocure INC. | $112.33 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $89.96 | 2024 | Libtayo |
| Ethicon US, LLC | $86.38 | 2019 | |
| Genentech USA, INC. | $82.57 | 2019-2025 | Tecentriq |
| Daiichi Sankyo INC. | $75.89 | 2024-2025 | Enhertu |
| Novocure Gmbh | $70.65 | 2022 | |
| Incyte Corporation | $70.45 | 2024-2025 | Pemazyre, Monjuvi, Jakafi |
| Janssen Biotech, INC. | $69.74 | 2024-2025 | Tecvayli, Darzalex, Talvey |
| Jazz Pharmaceuticals INC. | $69.08 | 2024-2025 | |
| Medical Device Business Services, INC. | $64.21 | 2021 | |
| R-Pharm US LLC | $59.48 | 2024 | Ixempra |
| Apellis Pharmaceuticals, INC. | $49.40 | 2024 | Empaveli |
| Beigene USA, INC. | $45.75 | 2024 | Brukinsa |
| Integra Lifesciences Corporation | $38.41 | 2024 | Duraseal Exact Spinal Sealant System, Codman Certas, Codman Hakim |
| Mirati Therapeutics, INC. | $35.47 | 2024 | Krazati |
| Alexion Pharmaceuticals, INC. | $25.82 | 2024 | Ultomiris |
| Puma Biotechnology, INC. | $25.46 | 2025 | |
| Iovance Biotherapeutics, INC. | $24.13 | 2025 | Amtagvi |
| Beone Medicines USA, INC. | $23.93 | 2025 | Tevimbra |
| Servier Pharmaceuticals LLC | $22.19 | 2024 | |
| Sobi, INC | $21.55 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $21.29 | 2024 | Onivyde, Somatuline Depot |
| Roche Diagnostics Corporation | $21.29 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.29 | 2022 | |
| Secura Bio, INC. | $15.02 | 2024 | Copiktra |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Shahin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.